NasdaqCM - Delayed Quote USD

Nutriband Inc. (NTRB)

3.7090 +0.1190 (+3.31%)
At close: May 14 at 4:00 PM EDT
Loading Chart for NTRB
DELL
  • Previous Close 3.5900
  • Open 3.6700
  • Bid 2.7000 x 200
  • Ask 4.7300 x 200
  • Day's Range 3.5201 - 3.8497
  • 52 Week Range 1.5300 - 5.9270
  • Volume 22,509
  • Avg. Volume 46,590
  • Market Cap (intraday) 40.687M
  • Beta (5Y Monthly) 0.51
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6900
  • Earnings Date Jun 7, 2024 - Jun 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

nutriband.com

--

Full Time Employees

January 31

Fiscal Year Ends

Recent News: NTRB

Performance Overview: NTRB

Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NTRB
59.87%
S&P 500
10.00%

1-Year Return

NTRB
13.95%
S&P 500
27.22%

3-Year Return

NTRB
--
S&P 500
20.42%

5-Year Return

NTRB
--
S&P 500
20.42%

Compare To: NTRB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NTRB

Valuation Measures

Annual
As of 5/14/2024
  • Market Cap

    40.69M

  • Enterprise Value

    40.44M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.15

  • Price/Book (mrq)

    6.32

  • Enterprise Value/Revenue

    19.39

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -263.05%

  • Return on Assets (ttm)

    -35.88%

  • Return on Equity (ttm)

    -73.08%

  • Revenue (ttm)

    2.09M

  • Net Income Avi to Common (ttm)

    -5.49M

  • Diluted EPS (ttm)

    -0.6900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    492.94k

  • Total Debt/Equity (mrq)

    3.75%

  • Levered Free Cash Flow (ttm)

    -1.79M

Research Analysis: NTRB

Company Insights: NTRB

Research Reports: NTRB

People Also Watch